Amgen News | Oct 11, 2024
Amgen celebrated its Mission Week by partnering with Let's Talk Science to support STEM education and strengthen Ontario's biomanufacturing sector...
Brought to you by RivalSense - an AI tool for monitoring any company.
RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡
Amgen
🌎 amgen.comAmgen is a leading biotechnology company that focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics for patients suffering from serious illnesses. With a commitment to harnessing biology and technology, Amgen aims to address high unmet medical needs across various therapeutic areas, including oncology, inflammation, and rare diseases. The company is recognized for its cutting-edge research and development efforts, contributing to a robust pipeline of medicines and earning accolades as one of the world's most innovative companies.
Amgen News & Insights as of Oct 11, 2024
- Amgen celebrated its Mission Week by partnering with Let's Talk Science to support STEM education and strengthen Ontario's biomanufacturing sector.
- Amgen will lead a global clinical study in collaboration with MediLink Therapeutics to evaluate the combination of YL201 and IMDELLTRA™ for treating extensive-stage small cell lung cancer.
- Amgen filed a lawsuit on October 4 against Fresenius SE & Co. to block biosimilars of its Prolia and Xgeva drugs, claiming infringement of 33 patents.
- Amgen launched The PARC, a platform for patients with or at risk of serious diseases, including cardiovascular disease.
- Amgen has reportedly stopped the distribution of Amgevita in Turkey, according to a Twitter post on October 11.
Sign up to receive regular updates
If you liked this report, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.
